Identification of NTRK fusions in pediatric mesenchymal tumors
Authors:
- 18 January 2017
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (8) , e26433
Abstract
Background: NTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the frequency of NTRK fusions in a large series of pediatric and adolescent patients with advanced cancers.Procedure: Genomic profiles from 2,031 advanced cancers from patients less than 21 years old who were assayed with comprehensive genomic profiling were reviewed to identify NTRK fusions.Results: Total of nine cases (0.44%) harbored NTRK fusions, including novel partners. Four of these cases were in children less than 2 years old for which infantile fibrosarcoma was considered as a diagnosis, and two harbored the canonical ETV6‐NTRK3. The remaining cases carried other diagnoses, at least one that carried the diagnosis of inflammatory myofibroblastic tumor.Conclusions: NTRK fusions occur in a subset of young patients with mesenchymal or sarcoma‐like tumors at a low frequency, and are eminently druggable targets via either investigational agents or approved drugs.Keywords
This publication has 22 references indexed in Scilit:
- MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer ResearchClinical Cancer Research, 2016
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid TumorsJAMA Oncology, 2016
- Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid TumorsJAMA Oncology, 2016
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibJNCI: Journal of the National Cancer Institute, 2015
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Cancer Discovery, 2015
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthJAMA, 2015
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- Congenital Mesoblastic Nephroma t(12;15) Is Associated withETV6-NTRK3 Gene FusionThe American Journal of Pathology, 1998
- A novel ETV6-NTRK3 gene fusion in congenital fibrosarcomaNature Genetics, 1998